"高特异性放射性碘（131I-MIBG）治疗转移性嗜铬细胞瘤/嗜铬细胞瘤的基于MIBG扫描的肿瘤反应标准建议。"
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma.
发表日期：2023 Apr 01
作者：
Yang Lu, Guofan Xu, Camilo Jimenez
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
高特异性放射性 131 I-MIBG（ A社楠达 ）是食品药品监督管理局批准的治疗转移性嗜铬细胞瘤和副神经节瘤的唯一疗法，这些是罕见的神经内分泌肿瘤，治疗选择有限。基于我们的经验，我们在此提出了基于功能成像的肿瘤反应标准，适用于这些患者群体。每个反应类别都以典型的样本案例说明，并提供了临床相关性。版权所有©2023 Wolters Kluwer Health, Inc. 保留所有权利。
High-specific-activity 131 I-MIBG (Azedra) is the only Food and Drug Administration-approved therapy for metastatic pheochromocytomas and paragangliomas, which are rare neuroendocrine tumors with limited treatment options. Based on our experience, we proposed here functional imaging-based tumor response criteria for these patient cohorts. Each response category was illustrated with typical sample cases, and clinical correlation was provided.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.